Clinical Trial Update: Pegfilgrastim-gema Compared to Pegfilgrastim-roche for Prevention of Induced Neutropenia in Breast Cancer Patients. [Phase 3]

View source ↗

Summary

Phase 3 trial comparing pegfilgrastim-gema to pegfilgrastim-roche for prevention of induced neutropenia in breast cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• pegfilgrastim-gema (pegfilgrastim-gema)
• pegfilgrastim-roche (pegfilgrastim-roche)

Snippet

Sponsor: Gema Biotech S.A. | Conditions: Breast Cancer | Phase 3 | Status: UNKNOWN